Patented Medicine Prices Review Board

Patented Medicine Prices Review Board
Conseil d'examen du prix des médicaments brevetés
Agency overview
Formed1987 (1987)
JurisdictionCanada
HeadquartersOttawa
Employees74
Annual budgetCA$10.3 million
Minister responsible
Agency executives
  • Tom Digby, Chairperson
  • Anie Perrault, Vice-Chairperson
  • Guillaume Couillard, Executive Director
Key document
  • Patent Act
Websitewww.canada.ca/en/patented-medicine-prices-review.html

The Patented Medicine Prices Review Board (PMPRB; French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada.

The mandate of the agency is to protect consumers by ensuring that the prices of patented medication charged by pharma companies are not excessive. The board also reports on trends, research and development in the Canadian pharmaceutical industry.

The PMRPB investigates, reviews and negotiates the price of drugs that are still under patent and which have no generic substitutes. It establishes the maximum prices that can be charged in Canada.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.